Globus Medical Q2 net sales up 18.4% to $745.3mln, GAAP net income $202.8mln.

• Globus Medical reports Q2 2025 net sales of $745.3mln, up 18.4%. • US Spine business grows 5.7%, highest sequential growth since Q2 2022. • GAAP net income for Q2 is $202.8mln and diluted EPS is $1.49. • Non-GAAP diluted EPS is $0.86.

Globus Medical (NYSE: GMED) reported robust financial results for the second quarter of 2025, with worldwide net sales of $745.3 million, marking an 18.4% year-over-year increase. The company's GAAP net income for the quarter reached $202.8 million, a remarkable 538.7% increase, driven primarily by a $110.6 million bargain purchase gain and a $34.8 million tax benefit. Key highlights include a 20.3% growth in U.S. net sales and an 11.0% increase in international sales.

The U.S. Spine business demonstrated particular strength, growing 5.7% (7.4% on a day-adjusted basis), which represents the highest sequential growth since the second quarter of 2022. GAAP diluted EPS reached $1.49, while non-GAAP diluted EPS was $0.86, reflecting a 14.1% year-over-year increase. The company's cash flow metrics showed $77.9 million from operations and $31.3 million in non-GAAP free cash flow.

Globus Medical reaffirmed its 2025 guidance, projecting revenue between $2.80-$2.90 billion and non-GAAP EPS of $3.00-$3.30. The company completed its Nevro acquisition and has begun working on synergy identification and execution. While Enabling Technologies showed only "modest bounce back," management expressed commitment to accelerating deal timelines in this segment.

The results reflect Globus Medical's continued focus on its long-term strategy of new product launches, organic growth, competitive rep recruiting, and robotic account pull-through. Management's commentary suggests confidence in continued momentum through the second half of 2025, with an emphasis on operational efficiency and profitable growth.

References:
[1] https://www.stocktitan.net/news/GMED/globus-medical-reports-second-quarter-2025-cu3gq1a0m5d2.html